{"689114":{"#nid":"689114","#data":{"type":"news","title":"ATDC Startups Secure Rare  FDA \u2018Breakthrough Device\u2019 Status ","body":[{"value":"\u003Cp\u003EIt\u2019s\u0026nbsp;uncommon\u0026nbsp;for any startup to receive the Food and\u0026nbsp;Drug\u0026nbsp;Administration\u2019s\u202f(FDA) Breakthrough Devices\u202fdesignation.\u0026nbsp;For the\u0026nbsp;roughly 40%\u0026nbsp;of applicants who receive the designation, it\u0026nbsp;shows that\u0026nbsp;the technology has real potential to improve patient outcomes and should get priority attention from the agency.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThe\u0026nbsp;\u003Ca href=\u0022https:\/\/atdc.org\/\u0022 target=\u0022_blank\u0022\u003EAdvanced Technology Development Center\u003C\/a\u003E\u0026nbsp;(ATDC)\u0026nbsp;in Georgia Tech\u2019s\u0026nbsp;\u003Ca href=\u0022https:\/\/commercialization.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003EOffice of Commercialization\u0026nbsp;\u003C\/a\u003Eannounced two of its\u0026nbsp;health technology\u0026nbsp;(HealthTech) portfolio\u0026nbsp;companies,\u0026nbsp;\u003Ca href=\u0022https:\/\/nephrodite.com\/\u0022 target=\u0022_blank\u0022\u003ENephrodite\u003C\/a\u003E\u0026nbsp;and\u0026nbsp;\u003Ca href=\u0022https:\/\/www.orthopreserve.com\/\u0022 target=\u0022_blank\u0022\u003EOrthoPreserve\u003C\/a\u003E, earned\u0026nbsp;the designation.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EAchieving this rare milestone\u0026nbsp;underscores\u0026nbsp;the caliber of founders, science, and support in ATDC\u2019s\u0026nbsp;30-company\u0026nbsp;HealthTech\u0026nbsp;portfolio, the incubator\u2019s largest focus\u0026nbsp;area.\u0026nbsp;It\u2019s\u0026nbsp;also a\u0026nbsp;win for\u0026nbsp;Georgia\u0026nbsp;because it\u0026nbsp;reflects\u0026nbsp;the strength of the state\u2019s\u0026nbsp;health\u0026nbsp;innovation\u0026nbsp;ecosystem.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cThis designation is one of the strongest signals the FDA gives that\u0026nbsp;a technology\u0026nbsp;could change the\u0026nbsp;standard of care,\u201d said\u0026nbsp;Greg Jungles, HealthTech catalyst at\u0026nbsp;ATDC.\u0026nbsp;\u201cFor ATDC to\u0026nbsp;have two in the same year is remarkable.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThe\u202fBreakthrough Device\u202fProgram\u0026nbsp;doesn\u2019t\u0026nbsp;waive evidence requirements, but it\u202faccelerates learning\u202fwith the FDA, ATDC\u2019s Jungles said. \u201cThat means shorter response times,\u202fmore frequent meetings, and\u202fprioritized review. Teams avoid dead ends and align earlier on study designs and endpoints.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EFor the founders\u0026nbsp;of both startups,\u0026nbsp;their technologies\u0026nbsp;come one step closer to moving their innovations to market.\u0026nbsp;Nephrodite\u2019s\u0026nbsp;technology\u0026nbsp;improves\u0026nbsp;the lives of dialysis\u0026nbsp;patients.\u0026nbsp;OrthoPreserve\u2019s\u0026nbsp;device addresses challenges faced by\u0026nbsp;those who suffer from chronic knee pain.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ENephrodite: Advancing Continuous Artificial Kidney Technology\u003C\/strong\u003E\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EDr. Nikhil\u0026nbsp;Shah\u0026nbsp;and Dr. Hiep Nguyen,\u0026nbsp;cofounders\u0026nbsp;of\u0026nbsp;Nephrodite, aim\u0026nbsp;to\u0026nbsp;improve\u0026nbsp;care for dialysis patients\u0026nbsp;with end-stage kidney disease\u0026nbsp;who need transplants. These patients\u0026nbsp;often\u0026nbsp;spend\u0026nbsp;three to four hours in a\u0026nbsp;dialysis\u0026nbsp;clinic\u0026nbsp;up to\u0026nbsp;three times a week. Being\u0026nbsp;tethered to stationary machines\u0026nbsp;with needles\u0026nbsp;drawing blood via arm grafts\u0026nbsp;complicates\u0026nbsp;everyday\u0026nbsp;activities\u0026nbsp;\u2014\u0026nbsp;from work\u0026nbsp;tasks\u0026nbsp;to the ability to travel.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EDialysis addresses chronic kidney disease, which means kidneys no longer work properly. The treatments filter out toxins,\u0026nbsp;waste, and other fluids in the blood. Kidney disease\u0026nbsp;\u003Ca href=\u0022https:\/\/www.cdc.gov\/kidney-disease\/ckd-facts\/index.html\u0022 target=\u0022_blank\u0022\u003Ecosts Medicare\u0026nbsp;$124.5 billion\u003C\/a\u003E\u0026nbsp;every year, according to the Centers for Disease Control and Prevention. And those costs are expected to rise because of increasing rates of kidney failure and chronic kidney disease.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cDialysis, while lifesaving\u0026nbsp;when it was pioneered\u0026nbsp;in 1952, is incredibly burdensome,\u201d Shah said.\u0026nbsp;Besides being\u0026nbsp;a long process\u0026nbsp;that keeps the patient in a fixed location,\u0026nbsp;it\u2019s\u0026nbsp;physically tiring.\u0026nbsp;\u201cTaking out your blood\u0026nbsp;continually\u0026nbsp;many, many times over, and over the course of four hours\u0026nbsp;is the equivalent of running\u0026nbsp;the Boston Marathon, hitting the finish line, and then someone saying, \u2018You\u0027re not done;\u0026nbsp;go do\u0026nbsp;it again,\u2019\u0026nbsp;\u201d\u0026nbsp;he said.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EA surgeon by training,\u0026nbsp;with\u0026nbsp;expertise\u0026nbsp;in transplantation and oncology, Shah\u0026nbsp;is also an adjunct associate professor\u0026nbsp;in\u0026nbsp;Tech\u2019s School of Interactive Computing. He\u0026nbsp;worked with\u0026nbsp;Nguyen\u0026nbsp;to develop a\u0026nbsp;continuously\u0026nbsp;functioning mechanical artificial kidney, leading to\u0026nbsp;Nephrodite\u2019s\u0026nbsp;formation.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThe\u0026nbsp;FDA\u2019s\u0026nbsp;breakthrough designation\u0026nbsp;on\u0026nbsp;its\u0026nbsp;artificial kidney\u0026nbsp;allows the company\u0026nbsp;to\u0026nbsp;pursue approvals to\u0026nbsp;begin tests in\u0026nbsp;human trials.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThe company traces its beginnings to a German aerospace facility outside Munich,\u0026nbsp;where\u0026nbsp;Nguyen and\u0026nbsp;Shah\u0026nbsp;watched engineers\u0026nbsp;demonstrate\u0026nbsp;a pediatric artificial heart\u0026nbsp;\u2014\u0026nbsp;the\u0026nbsp;\u003Ca href=\u0022https:\/\/www.berlinheart.com\/\u0022 target=\u0022_blank\u0022\u003EBerlin Heart\u003C\/a\u003E.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cThat\u2019s\u0026nbsp;how we got started,\u201d Shah said.\u0026nbsp;\u201cSeeing\u0026nbsp;an artificial heart that led us to\u0026nbsp;think about doing this for kidneys\u0026nbsp;\u2014\u0026nbsp;because the kidney space has been largely ignored for 70 years.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EBacked by a German federal grant,\u0026nbsp;Nephrodite\u0026nbsp;grew, moving from Germany to Boston, Massachusetts, then\u0026nbsp;to\u0026nbsp;Austin, Texas, before calling Atlanta home.\u0026nbsp;The\u0026nbsp;company joined\u0026nbsp;ATDC\u0026nbsp;and\u0026nbsp;tapped\u0026nbsp;into other Georgia Tech programs.\u0026nbsp;This\u0026nbsp;included\u0026nbsp;the\u0026nbsp;\u003Ca href=\u0022https:\/\/medtech.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003ECenter for MedTech Excellence\u003C\/a\u003E\u0026nbsp;and the\u0026nbsp;\u003Ca href=\u0022https:\/\/gamep.org\/\u0022 target=\u0022_blank\u0022\u003EGeorgia Manufacturing Extension Partnership\u003C\/a\u003E.\u0026nbsp;Nephrodite\u0026nbsp;also\u0026nbsp;drew on\u0026nbsp;student talent as\u0026nbsp;the researchers\u0026nbsp;quietly\u0026nbsp;worked\u0026nbsp;on\u0026nbsp;their\u0026nbsp;continuous mechanical artificial kidney.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ENephrodite\u0026nbsp;began\u0026nbsp;interviewing\u0026nbsp;patients\u0026nbsp;to\u0026nbsp;find out what they wanted\u0026nbsp;the artificial kidney needed to solve.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThey learned patients\u0026nbsp;want\u0026nbsp;the ability to be mobile.\u0026nbsp;Patients also\u0026nbsp;desire\u0026nbsp;an alternative\u0026nbsp;therapy to large needles being inserted into arm grafts\u0026nbsp;because the injection sites are prone to\u0026nbsp;infection\u0026nbsp;and the grafts can fail. In addition, the process\u0026nbsp;can\u0026nbsp;be\u0026nbsp;painful and disfiguring. Finally,\u0026nbsp;patients want\u0026nbsp;a quality of life\u0026nbsp;independent of\u0026nbsp;machines.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cThose\u0026nbsp;quality-of-life\u0026nbsp;needs, especially being free and mobile,\u0026nbsp;were\u0026nbsp;absolutely universal,\u201d Shah said.\u0026nbsp;\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ENephrodite\u0026nbsp;began developing the technology to\u0026nbsp;build\u0026nbsp;its device\u0026nbsp;\u2014\u0026nbsp;a filter surgically implanted in the pelvis area.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cWe developed an implant designed to run\u0026nbsp;constantly, connected to larger blood vessels\u0026nbsp;in the pelvis\u0026nbsp;to\u202favoid arm graft failures, and paired with an external interface that lets patients sleep at night while the system removes toxins and excess fluid,\u201d Shah\u0026nbsp;explained.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThe device also has\u0026nbsp;built-in sensors, with\u0026nbsp;data uploaded to the cloud,\u0026nbsp;enabling\u0026nbsp;medical care teams\u0026nbsp;to\u0026nbsp;remotely\u0026nbsp;monitor\u0026nbsp;their patients\u0026nbsp;while freeing\u0026nbsp;patients from frequent\u0026nbsp;in-clinic\u0026nbsp;visits.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EShah said\u0026nbsp;Nephrodite\u2019s\u0026nbsp;device\u0026nbsp;could restore everyday\u202findependence,\u0026nbsp;while potentially\u202flowering infection risk.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cIt\u0027s like having an actual kidney, but\u0026nbsp;without\u0026nbsp;all the issues\u0026nbsp;of an unhealthy one,\u201d Shah said.\u0026nbsp;\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EOrthoPreserve: Innovating a Minimally Invasive Meniscus Implant\u003C\/strong\u003E\u0026nbsp;\u003Cbr\u003E\u0026nbsp;\u003Cbr\u003EOrthoPreserve\u2019s technology aims\u0026nbsp;to address issues\u0026nbsp;from\u0026nbsp;people have with their meniscus,\u0026nbsp;the C\u2011shaped piece of cartilage in a knee joint that acts as a shock absorber between the thigh bone and shin bone.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EThough\u0026nbsp;patients undergo a now-routine surgery to address it,\u0026nbsp;incomplete recoveries are\u0026nbsp;also\u0026nbsp;common.\u0026nbsp;An estimated\u0026nbsp;quarter\u0026nbsp;of\u0026nbsp;patients\u202flater experience\u0026nbsp;recurring knee pain.\u0026nbsp;No FDA-approved implant\u202fcurrently exists for this population.\u0026nbsp;Now,\u0026nbsp;OrthoPreserveis developing a minimally invasive,\u202fartificial meniscus implant\u202fto\u202frestore cushioning,\u0026nbsp;relieve pain, and\u202fdelay\u0026nbsp;\u2014\u0026nbsp;or even\u0026nbsp;prevent\u0026nbsp;\u2014\u0026nbsp;knee replacement\u202ffor\u0026nbsp;some patients.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cThere are a million meniscus\u0026nbsp;surgeries every year, and 25% of those patients still live with recurring pain,\u201d said Jonathan Schwartz,\u0026nbsp;OrthoPreserve\u2019s\u0026nbsp;founder and CEO.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EPatients\u0026nbsp;can\u0026nbsp;face\u202fdaily pain\u202ffrom\u0026nbsp;ordinary activities, such as\u0026nbsp;prolonged\u0026nbsp;standing\u0026nbsp;or\u0026nbsp;walking\u0026nbsp;a dog. Other activities like\u0026nbsp;jogging and\u0026nbsp;recreational sports\u0026nbsp;can\u0026nbsp;trigger flares\u202fthat\u0026nbsp;can lead to\u0026nbsp;swelling and\u0026nbsp;prolonged\u0026nbsp;discomfort, Schwartz said.\u0026nbsp;\u201cThose patients have\u202fno\u0026nbsp;reliable\u0026nbsp;options today,\u201d he said. \u201cWe\u2019re building a minimally invasive implant to\u202frestore cushioning\u202fand help people get back to the activities they love.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EOrhoPreserve\u2019s\u0026nbsp;durable implant\u0026nbsp;restores cushioning, and it\u0026nbsp;could help people\u202freturn to normal activities\u0026nbsp;and\u202fdelay invasive knee replacement. Along with this comes\u0026nbsp;potential cost and recovery benefits for the healthcare\u0026nbsp;system.\u202f \u0026nbsp;\u003C\/p\u003E\u003Cp\u003ESchwartz\u202fcreated the implant as his\u202f\u003Ca href=\u0022https:\/\/research.gatech.edu\/tech-alum-launches-meniscus-implant-startup\u0022 target=\u0022_blank\u0022\u003EGeorgia Tech master\u2019s thesis\u003C\/a\u003E\u202fin the lab of\u202f\u003Ca href=\u0022https:\/\/www.me.gatech.edu\/faculty\/ku\u0022 target=\u0022_blank\u0022\u003EDavid Ku\u003C\/a\u003E\u202fin\u0026nbsp;the\u0026nbsp;Lawrence P. Huang Endowed Chair for Engineering Entrepreneurship and Regents\u0027 Professor\u0026nbsp;in\u0026nbsp;the\u0026nbsp;George W. Woodruff School of Mechanical Engineering. After industry experience,\u0026nbsp;Schwartz\u0026nbsp;returned to\u0026nbsp;further\u0026nbsp;develop\u0026nbsp;the\u0026nbsp;technology,\u0026nbsp;building on Georgia Tech\u2019s translational\u0026nbsp;expertise\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EOrthoPreserve\u0026nbsp;has completed\u202fmechanical testing and a successful\u202fstudy. The company\u0026nbsp;is raising a\u202f$2 million seed\u202fto complete validations and begin human trials, which Schwartz expects to start in\u0026nbsp;18 months.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cThe\u0026nbsp;FDA\u0026nbsp;breakthrough designation validates that nothing like this\u0026nbsp;technology\u0026nbsp;exists,\u0026nbsp;and that it has the potential to disrupt the standard of care,\u201d Schwartz\u0026nbsp;said,\u0026nbsp;adding the\u0026nbsp;U.S.\u2019\u0026nbsp;market\u0026nbsp;opportunity\u0026nbsp;is\u0026nbsp;roughly\u0026nbsp;$1.5 billion. \u201cWe finally have a minimally invasive\u0026nbsp;option to bridge the gap between meniscus surgery and knee replacement.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EWhat FDA Breakthrough Designation Means for\u0026nbsp;ATDC\u2019s\u0026nbsp;HealthTech Startups\u003C\/strong\u003E\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EHaving a\u0026nbsp;faster\u0026nbsp;and\u0026nbsp;clearer path is a\u202fderisking milestone\u202ffor investors\u0026nbsp;who are\u0026nbsp;evaluating\u0026nbsp;capital intensive\u0026nbsp;medical\u0026nbsp;device\u0026nbsp;technologies,\u0026nbsp;Jungles\u0026nbsp;said.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cThis\u0026nbsp;breakthrough device designation is a really big deal for medical\u0026nbsp;device companies,\u201d Jungles said, adding\u0026nbsp;that\u0026nbsp;startups often fear navigating the FDA\u0026nbsp;approval\u0026nbsp;process.\u0026nbsp;\u201cBut this designation\u0026nbsp;adds to the legitimacy of their technologies\u0026nbsp;and the problemsthey are solving. The designation will help them get to market faster, assuming their data continues to meet expectations.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EATDC launched its\u202f\u003Ca href=\u0022https:\/\/atdc.org\/industry\/healthtech\/\u0022 target=\u0022_blank\u0022\u003EHealthTech vertical\u003C\/a\u003E\u0026nbsp;in 2018,\u0026nbsp;which is\u0026nbsp;now\u0026nbsp;sponsored by\u0026nbsp;\u003Ca href=\u0022https:\/\/catalyst.wellstar.org\/\u0022 target=\u0022_blank\u0022\u003ECatalyst by Wellstar\u003C\/a\u003E\u0026nbsp;ATDC\u2019s HealthTech\u0026nbsp;portfoilo\u0026nbsp;companies\u0026nbsp;include\u0026nbsp;medical devices, biotech, and digital health, among other segments.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EATDC\u2019s Role in Accelerating HealthTech Innovation\u003C\/strong\u003E\u0026nbsp;\u003C\/p\u003E\u003Cp\u003ENephrodite\u0026nbsp;and\u0026nbsp;OrthoPreserve\u2019s\u0026nbsp;founders\u0026nbsp;noted\u0026nbsp;ATDC\u2019s\u202fcoaching\u0026nbsp;and\u0026nbsp;programming\u0026nbsp;as critical in navigating fundraising and regulatory milestones.\u0026nbsp;Another\u0026nbsp;factor, they said,\u0026nbsp;was\u0026nbsp;ATDC\u2019s\u0026nbsp;connection\u0026nbsp;to\u0026nbsp;Georgia Tech\u2019s\u0026nbsp;labs and facilities\u0026nbsp;and\u0026nbsp;prototyping support and clinical advisors\u0026nbsp;from\u0026nbsp;across\u0026nbsp;metro\u0026nbsp;Atlanta.\u0026nbsp;\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cWe meet with ATDC coaches every two to four weeks to troubleshoot and plan,\u201d Schwartz said. \u201cHaving that level of seasoned guidance, all\u0026nbsp;without consultant-level costs,\u0026nbsp;has been huge.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003EJungles added\u0026nbsp;that\u0026nbsp;two\u0026nbsp;Breakthrough device\u0026nbsp;designations in the same year\u0026nbsp;reflects\u0026nbsp;ATDC\u2019s selection rigor, noting\u0026nbsp;he\u2019s\u0026nbsp;evaluated hundreds of technologies since the HealthTech vertical launched.\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u201cIt reflects the caliber\u0026nbsp;of the companies in\u0026nbsp;ATDC, specifically in the medical\u0026nbsp;device space,\u201d Jungles said. \u201cIt\u2019s the strength of their teams, the persistence of the founders, and the collaboration of the ecosystem in Georgia and Atlanta.\u201d\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E","summary":"","format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003EFDA Breakthrough Device designation is rare for health technology startups.\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Milestone designation signals strong potential to reshape care for dialysis patients and those with chronic knee pain."}],"uid":"28137","created_gmt":"2026-03-20 21:15:57","changed_gmt":"2026-03-24 15:34:46","author":"P\u00e9ralte Paul","boilerplate_text":"","field_publication":"","field_article_url":"","location":"Atlanta, GA","dateline":{"date":"2026-03-20T00:00:00-04:00","iso_date":"2026-03-20T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"679705":{"id":"679705","type":"image","title":"Shah and Nguyen headshots","body":"\u003Cp\u003EDr. Nikhil\u0026nbsp;Shah\u0026nbsp;and Dr. Hiep Nguyen,\u0026nbsp;are cofounders\u0026nbsp;of\u0026nbsp;Nephrodite, an ATDC startup.\u003C\/p\u003E","created":"1774043491","gmt_created":"2026-03-20 21:51:31","changed":"1774043761","gmt_changed":"2026-03-20 21:56:01","alt":"Shah and Nguyen headshots","file":{"fid":"263896","name":"Screenshot-2026-03-20-at-17.49.33.png","image_path":"\/sites\/default\/files\/2026\/03\/20\/Screenshot-2026-03-20-at-17.49.33.png","image_full_path":"http:\/\/hg.gatech.edu\/\/sites\/default\/files\/2026\/03\/20\/Screenshot-2026-03-20-at-17.49.33.png","mime":"image\/png","size":289138,"path_740":"http:\/\/hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/2026\/03\/20\/Screenshot-2026-03-20-at-17.49.33.png?itok=tG6Q9aU1"}},"679703":{"id":"679703","type":"image","title":"Jonathan Schwartz headshot","body":"\u003Cp\u003EJonathan Schwartz,\u0026nbsp;OrthoPreserve\u2019s\u0026nbsp;founder and CEO.\u003C\/p\u003E","created":"1774042486","gmt_created":"2026-03-20 21:34:46","changed":"1774042827","gmt_changed":"2026-03-20 21:40:27","alt":"Headshot of Jonathan Schwartz.","file":{"fid":"263894","name":"J-schwartz-headshot_W.jpg","image_path":"\/sites\/default\/files\/2026\/03\/20\/J-schwartz-headshot_W.jpg","image_full_path":"http:\/\/hg.gatech.edu\/\/sites\/default\/files\/2026\/03\/20\/J-schwartz-headshot_W.jpg","mime":"image\/jpeg","size":514027,"path_740":"http:\/\/hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/2026\/03\/20\/J-schwartz-headshot_W.jpg?itok=fyQrz_1r"}}},"media_ids":["679705","679703"],"groups":[{"id":"655285","name":"GT Commercialization"},{"id":"1214","name":"News Room"},{"id":"1188","name":"Research Horizons"}],"categories":[{"id":"138","name":"Biotechnology, Health, Bioengineering, Genetics"},{"id":"139","name":"Business"},{"id":"131","name":"Economic Development and Policy"}],"keywords":[{"id":"4238","name":"atdc"},{"id":"194965","name":"Greg Jungles"},{"id":"194966","name":"Catalyst by Wellstar"},{"id":"14713","name":"FDA"},{"id":"189701","name":"breakthrough device designation"},{"id":"194967","name":"Nephrodite"},{"id":"194968","name":"OrthoPreserve"},{"id":"187915","name":"go-researchnews"}],"core_research_areas":[{"id":"193658","name":"Commercialization"},{"id":"193654","name":"Enterprise Innovation Institute"}],"news_room_topics":[{"id":"106361","name":"Business and Economic Development"},{"id":"71891","name":"Health and Medicine"}],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Cstrong\u003EP\u00e9ralte C. Paul\u003C\/strong\u003E\u003Cbr\u003E\u003Ca href=\u0022mailto:peralte@gatech.edu\u0022\u003Eperalte@gatech.edu\u003C\/a\u003E\u003Cbr\u003E404.316.1210\u003C\/p\u003E","format":"limited_html"}],"email":["peralte@gatech.edu"],"slides":[],"orientation":[],"userdata":""}}}